tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

OCUL Stock Latest News

Ocular Therapeutix Enters Quiet Period Ahead of SOL-1 Milestone
Company AnnouncementsOcular Therapeutix Enters Quiet Period Ahead of SOL-1 Milestone
21d ago
8K
OCUL
Strong Buy Rating for Ocular Therapeutix Backed by Enhanced Regulatory Pathway and Promising Axpaxli Trial Data
PremiumRatings
Strong Buy Rating for Ocular Therapeutix Backed by Enhanced Regulatory Pathway and Promising Axpaxli Trial Data
23d ago
OCUL
Ocular Therapeutix price target raised to $21 from $18 at BofA
PremiumThe Fly
Ocular Therapeutix price target raised to $21 from $18 at BofA
27d ago
OCUL
Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’
PremiumThe Fly
Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’
1M ago
EYPT
OCUL
Buy Rating for Ocular Therapeutix: Accelerated Axpaxli Launch and FDA Engagement Drive Positive Outlook
PremiumRatings
Buy Rating for Ocular Therapeutix: Accelerated Axpaxli Launch and FDA Engagement Drive Positive Outlook
1M ago
OCUL
Accelerated Market Entry for Axpaxli Boosts Ocular Therapeutix’s Competitive Edge: Buy Rating Justified
PremiumRatingsAccelerated Market Entry for Axpaxli Boosts Ocular Therapeutix’s Competitive Edge: Buy Rating Justified
1M ago
OCUL
Ocular Therapeutix up 13% at $14.22 on accelerated AXPAXLI NDA submission plans
Premium
The Fly
Ocular Therapeutix up 13% at $14.22 on accelerated AXPAXLI NDA submission plans
1M ago
OCUL
Ocular announces plans to accelerate AXPAXLI NDA submission timeline
Premium
The Fly
Ocular announces plans to accelerate AXPAXLI NDA submission timeline
1M ago
OCUL
Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright
PremiumThe Fly
Ocular Therapeutix price target raised to $21 from $19 at H.C. Wainwright
1M ago
OCUL
Strategic Early Approval Pathway for Ocular Therapeutix’s Axpaxli Bolsters Buy Rating
PremiumRatings
Strategic Early Approval Pathway for Ocular Therapeutix’s Axpaxli Bolsters Buy Rating
1M ago
OCUL
Ocular Therapeutix Prepares NDA Submission for Wet AMD Drug
PremiumCompany Announcements
Ocular Therapeutix Prepares NDA Submission for Wet AMD Drug
1M ago
8K
OCUL
Ocular Therapeutix reports inducement grant under Nasdaq listing rule
PremiumThe Fly
Ocular Therapeutix reports inducement grant under Nasdaq listing rule
1M ago
OCUL
Promising Developments in Ocular Therapeutix’s Clinical Trials Support Buy Rating
PremiumRatingsPromising Developments in Ocular Therapeutix’s Clinical Trials Support Buy Rating
1M ago
OCUL
Ocular Therapeutix announces first patient randomized in HELIOS-3 program
Premium
The Fly
Ocular Therapeutix announces first patient randomized in HELIOS-3 program
2M ago
OCUL
Ocular Therapeutix reports inducement grant under Nasdaq listing rule
Premium
The Fly
Ocular Therapeutix reports inducement grant under Nasdaq listing rule
2M ago
OCUL
Ocular Therapeutix Reports Q3 2025 Financial Results
PremiumCompany Announcements
Ocular Therapeutix Reports Q3 2025 Financial Results
2M ago
OCUL
Ocular Therapeutix Earnings Call: Optimism Amid Challenges
PremiumCompany Announcements
Ocular Therapeutix Earnings Call: Optimism Amid Challenges
2M ago
OCUL
Buy Rating for Ocular Therapeutix Driven by Promising Pipeline and Upcoming Clinical Trials
PremiumRatings
Buy Rating for Ocular Therapeutix Driven by Promising Pipeline and Upcoming Clinical Trials
2M ago
OCUL
Ocular Therapeutix price target raised to $21 from $18 at Clear Street
PremiumThe Fly
Ocular Therapeutix price target raised to $21 from $18 at Clear Street
2M ago
OCUL
Ocular Therapeutix’s Strategic Positioning and High Success Probability Support Buy Rating
PremiumRatingsOcular Therapeutix’s Strategic Positioning and High Success Probability Support Buy Rating
2M ago
OCUL
Ocular Therapeutix: Strong Execution and Promising Growth Prospects Justify Buy Rating
Premium
Ratings
Ocular Therapeutix: Strong Execution and Promising Growth Prospects Justify Buy Rating
2M ago
OCUL
Ocular Therapeutix achieves target randomization of 555 subjects in SOL-R
Premium
The Fly
Ocular Therapeutix achieves target randomization of 555 subjects in SOL-R
2M ago
OCUL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >